Moderna, Inc. (FRA:0QF)
Market Cap | 9.25B |
Revenue (ttm) | 2.62B |
Net Income (ttm) | -2.47B |
Shares Out | n/a |
EPS (ttm) | -6.41 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,807 |
Average Volume | 35,046 |
Open | 22.79 |
Previous Close | 23.94 |
Day's Range | 22.30 - 23.08 |
52-Week Range | 19.89 - 54.20 |
Beta | n/a |
RSI | 52.76 |
Earnings Date | Nov 7, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews

mRNA COVID shots may bolster effects of cancer treatments: study
mRNA-based COVID shots such as those from Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA) could lift survival of cancer patients on immunotherapies. Read more here.

Dow Jumps More Than 500 Points Ahead Of Earnings: Investor Fear Eases, Greed Index Remains In 'Fear' Zone
The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the “Fear” zone on Monday. U.S. stocks settled higher on Monday, with the Dow Jones inde...
Monday Sector Leaders: Healthcare, Technology & Communications
Looking at the sectors faring best as of midday Monday, shares of Healthcare companies are outperforming other sectors, higher by 1.5%. Within that group, Moderna Inc (Symbol: MRNA) and Cooper Compani...
Needham Reiterates Hold Rating for Moderna (MRNA) on October 20, 2025 | MRNA Stock News
Needham Reiterates Hold Rating for Moderna (MRNA) on October 20, 2025 | MRNA Stock News

Stock Market Today: S&P 500, Nasdaq, Dow Jones Futures Rise— Micron, Bitmine, Coinbase In Focus
U.S. stock futures rose on Monday following Friday’s advances. Futures of major benchmark indices were higher. On Sunday, President Donald Trump again warned that the U.S. economy would face significa...
Moderna (MRNA) Reveals Promising Data for Influenza Vaccines at IDWeek 2025
Moderna (MRNA) Reveals Promising Data for Influenza Vaccines at IDWeek 2025

Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, Octobe...

Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, Octobe...
Moderna Vs BioNTech: Who's Winning The Post-COVID Race
Moderna (MRNA) Reveals Promising Data from Cancer Study at ESMO 2025
Moderna (MRNA) Reveals Promising Data from Cancer Study at ESMO 2025
Moderna: More Downside In The Stock But The Cancer Vaccine Offers Potential
Moderna, Inc. (MRNA) Shareholder/Analyst Call Transcript
Moderna (MRNA) Shares Decline After Reporting mRNA-4359 Results
Moderna (MRNA) Shares Decline After Reporting mRNA-4359 Results
Moderna (MRNA) Shares Decline After Oncology Update
Moderna (MRNA) Shares Decline After Oncology Update

Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to r...

Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to r...

Why Moderna Might Be a One-Hit Wonder
Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.
SA analyst upgrades/downgrades: TSLA, MRNA, AVGO, CAG
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.
Moderna: Q3 Earnings Preview - I Fear A Halloween Horror Show (Downgrade)
Moderna (MRNA) Tops List of Most Shorted S&P 500 Stocks
Moderna (MRNA) Tops List of Most Shorted S&P 500 Stocks
Moderna (MRNA) Unveils Promising Data on mRNA-4359 for Melanoma Treatment
Moderna (MRNA) Unveils Promising Data on mRNA-4359 for Melanoma Treatment
Moderna (MRNA) Tops Healthcare Short Interest Rankings
Moderna (MRNA) Tops Healthcare Short Interest Rankings

Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients
Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkp...

Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients
Moderna's Phase 1/2 study shows mRNA-4359 ... Full story available on Benzinga.com